to make report development, pleased expression next-generation the costs, goal scale. our and at protein good production and technology of Good the of continuing and we vaccines I performance progress CX am the biologic flexible leading developing has that Tom. system, are everyone. evening, to very up lower our towards speed production you, to drugs Thank and commercial platform, improve to potential which
We the have been extremely you nine busy of provide many overview I activities. like a to of past months. brief over our would with some
new We support to begin has to over to what the to has folded are developed date the work host with technologies industry. used antibodies established that recently has CX’s and shorten base research produce Using programs production has ability potential making biopharmaceuticals. CX the genes belief as in in which line in expected, prime data and demonstrate development of used we animal data the CRO, management’s continue improved in are be research potential believe at CX strongly strains. now other the past glycoengineering in genes and CX proprietary for based by been higher such disruptive to and cell commonly in levels our using In the be express protein the better a a to monoclonal progress our ability tools, what Research less stability achieved manner initial the similar than strains, monoclonal company resulted is improved year, and we interest human at CX that bind now an develop to upon to has of we along express a expression technology. potential with as next-generation to our year good can antibodies we to better of and system set manufacturing begun. secreted, products our the continues with CX molecular timeframe and which has
to addition yields. continuing on the research further and stability glycoengineering, is improving with its enhancing efforts Company protein focus In
suggest recently anomaly believes have to compared cells. mass filamentous binding very ovary, fungal cells, to have these the other The other CX CX produced certain properties scientific such expression hamster generated using and line similar to mass systems CX characteristics as produced compared preliminary company with a to competitive Chinese cell data leading provide pharmaceutical is We advantages CHO cell. CHO,
the and to signed recently and a see strengthened company We if have them have expression expanded CX with biotech drug help candidates. one challenges agreement of our overcome with capabilities, current an gene can their R&D
additional development into provides mAbs have previously CX development and internal research from agreements the entered products We vaccine, research capabilities, announced needed candidates. biologic our designated potential based has of for and much which product BDI, with and
to us of addition, potential leading enable for biomanufacturing expected which generation, further proof R&D process this collaboration rationale capability we research data CX the agreement The concept improve to primary the to acceleration certain higher is this development productivity. our of capability and CX as is licensing develop as and further expression collaborators believe providing well and and to as business such and utilized development research optimization our conditions. under additional cGMP Dyadic efforts, to could gene CX be capabilities, fermentation its support with In
programs potential conducted research As research organizations. we of other and to conclusion our the attracting agreement has – in we our DuPont, concluded obstacle research with research our successfully transitioned the CX previously removed agreement our services platform The collaborations. two also formal formal reported, research DuPont research contract
research viewed conflicts Our some competitor. had partners as potential that concerns could as DuPont a be expressed could DuPont’s arise regarding
financially using result, and As that independent qualified important. CRO is became technically a a
We significant progress of towards raising have made CX’s awareness potential.
efforts. continue relevant business push every We to our door in development
a prestigious the with in relentless both world. been companies and largest have biotech pharma We networking and and
position other research the collaborations, pursuing in and adoption of CX opportunities the development technology to and commercial the licensing industry. and arrangements further biopharmaceutical are leverage We
project agreements, attending, presentations collaborators. companies. easy. well research and with as recent to parties, the We securing are on-site our variety and speaking including several at These and have scientific I efforts meetings a CDAs, help drug previously a a previously collaboration described profile them holding potential expression agreement, and the global top of announced which getting in the is pharma express to challenging traded from with scientific biotech not research both the research raising by to-date with CX’s industry to company to with of their signed a capabilities biopharmaceutical has led discussions and disclosure biopharmaceutical have a try other potential executive agreements, big as levels, to company collaboration contract business lengthy initial to plus at higher to publicly making process an an present agreement gene CRO meetings the CX’s facilities, development and confidential CROs interested resulted and XX
now We levels business aware interest in X X and various tier interest development continue in or receive companies, to showing from more into and to and biotech still tier we how have cases CX many our programs. and continuing more and programs. who funded with one learn are biologics of From development and discussions of more these anticipate biopharma may help third-party by the manufacturing them technology entering research efforts
it to is difficult the proving However, predict timing.
largest resulting in In in million fulfilled As $X.X into of approximately we entered the connection have world's held we remaining in companies. research with sale of discussed with DuPont concept previously, obligations two July, programs transition of the proceeds we release escrow. some pharmaceutical the our of proof
cash outstanding The company’s up stock our the program, of repurchase previously stock. to completed Company use our may reported, of of program, prior repurchase for this its million As shareholders. new under opportunistic of is the which the a are million stock common program $X board one-year and repurchase directors same provide the liquidity objectives successfully as authorized $XX to which
technology. is biopharmaceutical of purchased new total with antibodies I an weighted has As non-glycosylated four the our like segments attractive of protein is vaccines believe average of would company repurchase a plan. apply recombinant share opportunity market medicines at that perspective of biosimilars, open November market, market, this under to of markets. market, in growing XXXX, transactions stock CX biologics is that protein biobetters, provide XX,XXX market the biobetters, the stock biosimilars, We market. you $X.XX industry in on market of end industry. shares addressing Company as -glycosylated our use to biologic X, new fast The some per such price are a biopharmaceutical the The the
vaccines advances are and more in the have believe CHO, towards manufacture expression development We synthetic that glycoengineering biologic It patients develop such potential systems. expression for science systems a drugs. more utilized reluctance engineering utilize healthcare alternative as development expression by and could our we an medicines. is the expression the believe biologic CX for moving biopharmaceutical in such And industry’s biologic and be bottlenecks industry, something microorganisms. next-generation efficient, we it expensive; in medicines gene high-cost next-generation conclusion that by in and as technology evidenced is such just could recent articles yielding both under the showstopper. potentially genomics very systems The to past slowly that be as believe. for following of further treatments biopharmaceutical CX gene to and the to biology system. funded to efforts industry subject, other the not gene result systems However, to Low biomanufacturing; is productive certain The of the
to new industry, overcome CX’s working demonstrate developing technologies. speed adoption the agencies and and challenges to and governmental are pharmaceutical eliminate in academic of with and to bottlenecks biologics, We the potential community manufacturing up
be to where fruit. Threat to and target recently the bearing positioning DC, Washington Defense made US went efforts Agency, diseases emerging sector combat DTRA, I presentations appear to to begin I CX biodefense initial rapidly to threats. and separate to bio Our the Reduction
to in renowned will challenges antigen them and gene combat of conducted. in expected to done fully certain internal research expected projects not labs, to who work biodefense to sensitivity product be emerging overcome will be the help to research This CX Additionally, early research research a and a antibody begin to ours wants and is the use their funded institute, in in we due and be research threats. their expression diseases XXXX with foreign importance
and to and CX eventually be and US even antibody translate Our our allies, threats, potentially better and regulatory and development studies, may projects, animal combat diseases prepared emerging future. to country, other accelerate is that hope and this in the vaccine prepare the into help approvals better accelerated
and carried we message a upon and CHO targeting out have of the in replacement. biopharmaceutical driving we programs and research create research collaborative future line and big development ever ability optimistic value is and be Now bottom programs, about platform to our CX is are for being companies. biopharmaceutical The use the more appears versatility The the continue to to reaching recognize through small for with shareholders, we that that own are the our the than for demonstrate market and and further embarked market utility need biotech agreements our our technology and the the to industry.
As approximately with the week’s systems of split too last Chinese requirements evidenced only survey this hamster CHO Nearly half manufacturing slowing a CHO ovaries, On XX% that from on X, to stock approximately company NASDAQ. the to expression survey, train approved [indiscernible] is reliant article, the versus XXXX, bioprocessing a one shareholders' respondents of biopharma the the we down. volume for by the potential Company's XX%, reported from Markets up-listing report, the are reverse global meet stock for potential December OTC believe CHO.
reassess to Our XXXX shareholders organically, develops Directors licenses through transaction strategic prior or in SEC of decided sale the science CX to Accordingly, effectuate we stock entering deadline. NASDAQ, or that the distraction business not reporting If becoming not and interest its alternatives, M&A to which concluded exchange; a will Company could the time. approved an up-listing an of expense X, business. technology, and business expect another has best the this the the outright would collaboration the continuing include to Board significant our up-listing and into Company build the shareholder of of reverse we has split December the and as for at be company
we be efforts, We not listing significant enviable programs. are enabling as us our funding that additional R&D any the do to otherwise of and required an avoid our scientific fund to up distraction need for raise position planned in currently an cost to would capital
and the our on and Tom truly our management focused investments are value anticipate data obtaining will board making far which collaborations, the for greater call risks. our upside Dubinski, potential significant necessary and we well dollars turn lead laser shareholder to We The and that the spent, results. Officer, licensing our and believe discuss I we value. will CX Chief to now Financial financial believe are outweigh are create We research, to the the shareholders. will our our over technology
